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Alveolar soft part sarcoma (ASPS) is a very clinically 
and morphologically unique soft tissue sarcoma which 
was first defined and named by Christopherson et al.1) in 
1952. It is known to comprise 0.5%–1% of all soft tissue 
sarcomas, and it occurs in teenagers and young adults 
under forty years of age.2,3) It usually occurs in the trunk 
and lower extremities, but is also found in the genital area, 
breasts, mediastinum, bladder, gastrointestinal, orbital 
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area, and tongue.4) ASPS is found as a slowly growing soft 
tissue mass. It is first diagnosed by symptoms produced by 
metastasis into the lungs and brain because it is diagnosed 
late in time since it has no related symptoms. The term 
“alveolar” originated from the polygonal cells histologi-
cally gathered to form a pseudo-alveolar shape. Pathologi-
cally, it is not difficult to diagnose because the rhomboid-
shaped crystalline materials are observed in the cytoplasm 
when it is dyed with periodic acid schiff (PAS), but in 
magnetic resonance imaging or contrast-enhanced com-
puted tomography (CT), it can be confused as a heman-
gioma which is much more common and has a rich supply 
of blood vessels. In this manner, ASPS can occur anywhere 
in the trunk or extremities, but its occurrence is very rare, 
and clinicians have little experience of treatment. Because 
of the rarity of the disease, most reports relating to ASPS 
are in the form of case reports or small series. In this 
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study, through 19 cases of pathologically confirmed ASPS, 
we analyzed the clinical aspect, therapeutic method and 
therapy results. 
METHODS
We performed a comprehensive retrospective review of 
the medical records of patients who were pathologically 
confirmed between 1996 and 2011 (n = 19), and we per-
formed an investigation of image tests such as simple X-
rays, angiographies, contrast-enhanced CTs and magnetic 
resonance images (MRIs), as well as of pathological biopsy 
results and follow-up evaluations. This study was approved 
by Yonsei University Health System, Severence Hospital, 
Institutional Review Board (IRB# 4-2012-0699). The ana-
tomical location and depth of the mass, clinically assumed 
diagnosis of the first medical examination doctor, size of 
mass, surgical method, whether it metastasized at the time 
of diagnosis or during follow-up and the site of metastasis, 
and survival rate were studied.
The depth of the mass was classified as “superficial” 
when the mass didn't invade the deep fascia and as “deep” 
when it invaded the deep fascia in image tests (MRI, CT, 
or ultrasonography) performed before the operation. The 
size of the mass was measured by the longest axis in cen-
timeters in pathological biopsy tests after the surgery (Fig. 
1). All macroscopically complete resections were classi-
fied according to the closest surgical margin, which was 
microscopically categorized as positive (tumor within 1 
mm from the inked surface, R1) or negative (absence of 
tumor within 1 mm from the inked surface, R0). Locally 
recurrent disease was defined as tumor occurrence at a site 
previously treated for ASPS. Recurrance and survival was 
analyzed via the Kaplan-Meier method.
RESULTS
Clinical Features
In the total of 19 patients, 6 were men and 13 were women, 
so the group of women was a little larger. The mean age 
of patients was 30.3 years old, ranging from 10 to 64 years 
old. The patients had follow-up at longest for 14 years and 
8 months with a mean of 54 months. Fifteen cases (78.9%) 
visited with a painless mass as a chief complaint, 4 cases 
(21.1%) complained of a mass accompanied by pain and 
discomfort. From the start of the symptoms to the hospital 
Fig. 1. A 14-year-old female patient presented with a chief complaint of growing palpable mass in the anterior aspect of the left mid thigh. (A) On 
the plain radiography of the left femur, soft tissue shadow was seen in the anterior aspect of the midshaft of the femur. (B) On T2-weighted coronal 
magnetic resonance image, there was a 7 × 5 × 3 mm-sized, well-enhanced soft tissue mass at the same site. (C,D) On computed tomography 
angiogram, a highly vascularized mass lesion was observed, and tortuous prominent blood vessels were seen on superior and inferior margins of the 
mass. (E,F) There was no metastasis seen on positron emission tomography computed tomography. (G) Incisional biopsy was performed and the mass 
was diagnosed as alveolar soft part sarcoma. A wide marginal excision was performed.
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visit, the longest time lasted 60 months with 15 months as 
the average.
The tumor was located in the trunk in 5 cases (26%) 
and in a lower extremity in 14 cases (74%). The clinical 
assumptive diagnosis made by the first medical examiner 
was a benign soft tissue tumor in 5 cases (26%) and benign 
hemangioma in 4 cases (21%). In the 15 cases where we 
could do the image test before the surgery, the mass was 
located in deep areas in 10 cases (67%), throughout the 
deep and superficial areas in 5 cases (33%), and none were 
located in superficial area only. The tumor size was 55 mm 
(10–130 mm) on average. It exceeded 50 mm in 9 cases 
Fig. 2. (A) From a total of 19 cases, the 
mass was located in the trunk in 5 cases 
(26%) and thigh in 14 cases (74%). (B) 
During the first medical examination, 
benign soft tissue tumor was diagnosed 
in 5 cases (26%) and benign hemangioma 
in 4 cases (21%). (C) In the 15 cases in 
which magnetic resonance imaging was 
performed before the surgery, the mass 
was deep seated in 10 cases (67%) and 
located from subcutaneous layer to deep 
layer in 5 cases (33%). (D) Mass size 
exceeded 50 mm in 9 cases (47%), and it 
was less than or the same as that in 10 
cases (53%). STT: soft tissue tumor.
Fig. 3. (A) Eight cases were transferred 
from other hospitals after surgery: 
unplanned excision in 6 cases and biopsy 
only in 2 cases. (B) Eight cases had 
metastases at the time of diagnosis: 
lung metastasis in 5 cases and multiple 
metastases in 3 cases (16%). (C) Among 
the cases with an operation at our 
hospital, the mass was classified as 
R0 in 11, R1 in 5, and R2 in 3. (D) In 
the 11 cases without metastases, lung 
metastasis was found in 2 and multiple 
metastases in another 2 during the 
outpatient follow-up. meta: metastasis.
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(47%) and it was the same or less than 50 mm in 10 cases 
(53%) (Fig. 2).
Therapeutic Results
In 8 cases, patients were transferred from other hospitals 
or institutes after surgery. Among those, 6 cases (32%) 
had an unplanned mass excision, and 2 cases (10%) had a 
biopsy and transferred afterwards. Eight cases already had 
metastasis in other organs at the time of diagnosis. Among 
those, 5 cases (26%) had lung metastasis, and 3 cases (16%) 
had 2 or more multiorgan metastases including those in 
the bone and intracranial space. Among patients who had 
surgery performed in our hospital, 11 cases (16%) had R0, 
5 cases (26%) had R1, 3 cases (16%) had R2. Among 11 
cases that had no metastases, 4 cases had metastasis ob-
served during outpatient department follow-up. Lung me-
tastases were found in 2 cases, and multiorgan metastases 
was found in 2 cases (Fig. 3). In 5 cases, additional surgical 
intervention was performed after the first surgery. In 8 
cases (42.1%), radiation was added (total radiation 60 Gy), 
and in 10 cases (52.6%), chemotherapy was performed (Fig. 
4).
In total, 3-year survival was 78.9% and 5-year sur-
vival was 52.6%. In survival classified by surgical resection 
margin, RO 3-year survival was 100%, and 5-year survival 
was 80%, which were higher than those of R1 or R2 in 
terms of long-term survival. In tumor size, survival was 
70% in patients with smaller than 50 mm at final follow-
up, which was better than tumors sized more than 42.9%. 
Also when there is no other organ metastasis, long-term 
survival was better than in cases with metastasis (Fig. 5). 
There was no meaningful difference in final follow-up 
survival according to depth of the tumor. 
DISCUSSION
Alveolar soft tissue sarcoma has low occurrence, and 
there is a report that states it is more common in female 
patients.3) It is known to most frequently invade lower 
extremities, second frequently the trunk, and lower ex-
tremities the least. In this study, female patients were more 
than double in number than male patients, and the lower 
extremities were the most common sites of invasion, the 
trunk the second most common. Alveolar soft tissue sar-
coma has slow-growing characteristics, and because of this 
metastasis to other organs were found in 20%–40% at the 
time of diagnosis. Metastasis usually invades the lung, and 
there is a report of lung metastasis found 35 years after 
surgical removal of the primary cancer.5) Following lung 
metastases, bone and intracranial metastases are common, 
but lymph node metastases are not common.3,6)
Alveolar soft tissue sarcoma usually shows high 
signal in T1-weighted and T2-weighted MRI and features 
internal and external multilobulated signal change.7-9) The 
part with a high signal in T1-weighted MRI has low blood 
flow rate, and the part with multilobulated signal change 
Fig. 4. (A) Eight cases (42%) had radiation therapy after operation. (B) Ten cases (53%) had 
adjuvant chemotherapy. (C) Five cases (26%) had an additional operation.
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in T1-weighted and T2-weighted MRI has high blood flow 
rate, relatively. This is a characteristic feature of alveolar 
soft tissue sarcoma.8) In angiography, expended feeding 
and efferent vessels are seen inside and around the tumor, 
and these findings are similar to arteriovenous malforma-
tion, so it is easy to misdiagnose.6,8) When doing image 
studies for alveolar soft tissue sarcoma, hemangioma, 
arteriovenous malformation, clear-cell sarcoma, meta-
static malignant melanoma, liposarcoma, and soft tissue 
sarcoma with internal bleeding are needed for different 
diagnoses. These lesions have high signal intensity in T1-
weighted MRI or have similar signal intensity as muscle. 
In clear-cell sarcoma, multilobulated signal change is not 
seen, and it is not easy to differentiate with hemangioma 
or arteriovenous malformation, but the fact that the solid 
tissue component seen in alveolar soft tissue sarcoma is 
not seen in these lesions helps to differentiate alveolar soft 
tissue sarcoma.8)
According to the depiction first performed by 
Christopherson et al.,1) histologically, alveolar soft tissue 
sarcoma is relatively big and has a tube shaped nucleolus 
and eosinophilic cytoplasm, and, structurally, alveolar 
soft tissue sarcoma has polygonal tumor cells forming an 
organoid nest and has a unique morphological pattern, 
called Pseudoalveolar pattern, which is divided by capil-
lary sized vascular channels and tube shaped septum. 
Clear cell change is definite and this sometimes needs dif-
ferential diagnosis with metastatic renal cell carcinoma. 
Renal cell carcinoma can be distinguished by associated 
past history, clinical symptom, radiologic evaluation, etc. 
Renal cell carcinoma is positive in immunohistochemical 
staining to cytokeratin and vimentine, so it is not difficult 
to differentially diagnose from alveolar soft tissue sar-
coma. Diseases to differentially diagnose histologically are 
Fig. 5. (A) Overall 3-year survival rate was 78.9%. (B) The long-term survival rate was higher in R0 than R1 and R2 classified according to the quality of 
surgery. (C) The long-term survival rate was higher in patients with a tumor ≤ 50 mm in diameter than those with > 50 mm. (D) The long-term survival 
rate was higher in cases without metastases than in cases with metastases. 
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paraganglioma, adrenal cortical carcinoma, hepatocellular 
carcinoma, alveolar rhabdomyosarcoma, malignant mela-
noma, granular cell tumor, etc.10,11) Paraganglima has an 
alveolar structure and is positive in immunohistochemical 
staining to chromogranin and synaptophysin. Metastatic 
adrenal cortical carcinoma and hepatocellular carcinoma 
can be differentiated each by melan-A-cross reactivity 
and Hep Par staining. Alveolar rhabdomyosarcoma can 
be distinguished by myogenin and MyoD1 staining in 
skeletal muscles, and malignant melanoma can be distin-
guished by staining in melanocytes such as S-100 protein 
and HMB45. Granular cell tumor doesn't have crystalline 
bundles specifically seen in alveolar soft tissue sarcoma 
and has positive reaction to S-100 protein.
Pennacchioli et al.12) reported that 10-year survival 
after surgical resection of alveolar soft tissue sarcoma is 
53.4%, informing that tumor size and classification of sur-
gical resection margin are related with patient prognosis. 
Ogose et al.13) reported that when tumor size is less than 5 
mm, 5-year, 10-year, 15-year survival are 72%, 65%, and 
65%, respectively, and when it is larger than 5 mm, each 
are 46%, 9%, and 0%, respectively. Alveolar soft tissue 
sarcoma is a relatively slow growing tumor, and the larger 
the tumor size, the longer ago it started and had had more 
opportunity to metastatize into other organs. Reports of a 
larger tumor size with more metastases found in other or-
gans support this assertion.14,15) With respect to the surgi-
cal margin of alveolar soft tissue sarcoma, the influencing 
prognosis is known from many previous reports, and most 
tumor specialists agree that it is most important for the full 
recovery of a local tumor. For this, en-bloc of the tumor 
with sufficient amount of normal cells surrounding the 
tumor should be possible. The larger the size of the tumor, 
the lesser the opportunity of en-bloc including the tumor, 
so tumor size can influence surgical margin. Discovery of 
tumor cells in the surgical margin means active tumor cells 
are left and need more aggressive treatment. Recurrence 
of alveolar soft tissue sarcoma is reported to be 20%.3) 
Sherman et al.16) reported radiation treatment of alveolar 
soft tissue sarcoma, suggesting radiation treatment as the 
treatment rule for alveolar soft tissue sarcoma. Ogose et 
al.13) suggested supplemental radiation treatment is needed 
when the surgical margin is insuffient, but until now there 
are no reports of radiation treatment and anticancer treat-
ment influencing prognosis.13,17) In this study, 3 cases of R2 
resection were carried out with radiation treatment and 
anticancer treatment after surgery, but after follow-up of 
5 years, all had expired. Whereas the 5-year, 10-year, and 
15-year survival of patients without metastasis at the time 
of diagnosis were all 81%, 5-year survival of patients with 
metastasis at the time of diagnosis was 46% and 10-year 
survival was 0%.13)
Alveolar soft tissue sarcoma patients mostly came to 
the hospital due to a painless mass as the chief complaint 
and presented symptoms clinically similar to benign hem-
angioma, so biopsies were performed as needed. Treat-
ment principle was of a massive resection, and when the 
surgical margin is questionable, radiation treatment can 
be added for prevention of local recurrence. Also, with the 
discovery of metastasis and local recurrence, even after 5 
years of general treatment, outpatient department follow-
up is needed, and we need to keep in mind that lung, in-
tracranial, and bone metastases are common.
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